SEC filing

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

Retrieved on: 
Friday, September 16, 2022

The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.

Key Points: 
  • The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $80.5 million.
  • Guggenheim Securities, LLC acted as lead book-running manager for the offering and William Blair & Company, L.L.C.
  • The shares were offered by Larimar pursuant to an effective shelf registration statement on Form S-3 (File No.
  • Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.

Technip Energies Awarded an EPCC Contract for YURI Green Hydrogen Project in Australia

Retrieved on: 
Friday, September 16, 2022

Technip Energies (Paris:TE) (ISIN:NL0014559478), leader of a consortium with Monford Group, has been awarded an Engineering, Procurement, Construction and Commissioning (EPCC) contract by Yuri Operations Pty Ltd, to develop Project Yuri Phase 0 project which is a green hydrogen plant in the Pilbara region of Western Australia.

Key Points: 
  • Technip Energies (Paris:TE) (ISIN:NL0014559478), leader of a consortium with Monford Group, has been awarded an Engineering, Procurement, Construction and Commissioning (EPCC) contract by Yuri Operations Pty Ltd, to develop Project Yuri Phase 0 project which is a green hydrogen plant in the Pilbara region of Western Australia.
  • Yuri project is an important milestone paving the way for an accelerated deployment of green hydrogen capacity to decarbonise the industry.
  • While Technip Energies believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting Technip Energies will be those that Technip Energies anticipates.
  • All of Technip Energies forward-looking statements involve risks and uncertainties (some of which are significant or beyond Technip Energies control) and assumptions that could cause actual results to differ materially from Technip Energies historical experience and Technip Energies present expectations or projections.

Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering

Retrieved on: 
Friday, September 16, 2022

HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the Company or Nexalin) today announced the pricing of its initial public offering of 2,315,000 units consisting of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common stock.

Key Points: 
  • HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the Company or Nexalin) today announced the pricing of its initial public offering of 2,315,000 units consisting of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purchase up to 2,315,000 shares of common stock.
  • Maxim Group LLC is acting as the sole book-running manager in connection with the offering.
  • This press release contains statements that constitute "forward-looking statements," including with respect to the Companys initial public offering.
  • No assurance can be given that the offering discussed above will be completed on the terms described, or at all.

Know Labs, Inc. Announces Pricing of Upsized $7.2 Million Public Offering of Common Stock and Uplisting to the NYSE American Exchange

Retrieved on: 
Thursday, September 15, 2022

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $2.00 per share (the "Offering").

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $2.00 per share (the "Offering").
  • The aggregate gross proceeds from the Offering are expected to total $7.2 million before deducting the underwriting discounts and commissions and estimated Offering expenses payable by Know Labs.
  • Know Labs common stock is expected to begin trading on the NYSE American Exchange under the ticker symbol "KNW" on September 16, 2022.
  • Know Labs, Inc. is a public company whose shares will trade on the NYSE American Exchange under the stock symbol KNW.

Multi-omics service provider Sequanta completes extended concordance validation of Olink® Target 48/96 and Olink® Explore

Retrieved on: 
Thursday, September 15, 2022

The Company was founded in 2016 and is well established across Europe, North America and Asia.

Key Points: 
  • The Company was founded in 2016 and is well established across Europe, North America and Asia.
  • Sequanta Technologies is a leading multi-omics research and clinical service provider in China, focusing on genomics, proteomics and related services to support pharmaceutical clients in biomarker discovery and clinical trials.
  • Sequanta provides diversified genomics and proteomics assays validated by research standard and CAP standard, which include genotyping and gene expression qPCR assays, NGS assays and protein biomarker detection assays.
  • Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olinks strategy, business plans and focus.

Revance Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Thursday, September 15, 2022

The aggregate gross proceeds from the public offering were $230.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Key Points: 
  • The aggregate gross proceeds from the public offering were $230.0 million, before deducting underwriting discounts and commissions and other offering expenses.
  • Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC acted as joint book-running managers for the offering.
  • The securities described above were offered by Revance pursuant to an automatic shelf registration statement on Form S-3 (File No.
  • Revance, the Revance logo and OPUL are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are registered trademarks of Teoxane SA.

Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville

Retrieved on: 
Thursday, September 15, 2022

FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that it entered into a Pre-Paid Advance Agreement (the Agreement) with YA II PN, LTD (Yorkville), an affiliate of Yorkville Advisors Global, LP.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced that it entered into a Pre-Paid Advance Agreement (the Agreement) with YA II PN, LTD (Yorkville), an affiliate of Yorkville Advisors Global, LP.
  • Under the Agreement, Celularity may request individual pre-paid advances from Yorkville in an amount up to $40 million each subject to certain conditions, up to $150 million over the next eighteen (18) months from time to time and as mutually agreed by the parties.
  • Pre-paid advances are issued at a 2% discount, bear interest at a rate of 6% (increased to 15% in the event of default).
  • Celularity intends to use the proceeds for working capital and other general corporate purposes.

SunPower invests in leading solar dealers Renova Energy and EmPower Solar

Retrieved on: 
Thursday, September 15, 2022

RICHMOND, Calif., Sept. 15, 2022 /PRNewswire/ -- SunPower (NASDAQ:SPWR), a leading residential solar technology and energy services provider, today announced it has made minority investments in EmPower Solar and Renova Energy. With these investments, Renova and EmPower are the newest additions to SunPower's Dealer Accelerator Program.

Key Points: 
  • SunPower Dealer Accelerator Program designed to propel solar dealer growth and accelerate proliferation of SunPower's solar, storage and financing products
    RICHMOND, Calif., Sept. 15, 2022 /PRNewswire/ -- SunPower (NASDAQ:SPWR), a leading residential solar technology and energy services provider, today announced it has made minority investments in EmPower Solar and Renova Energy.
  • Dealers in the program exclusively sell industry leading SunPower solar systems.
  • Through these investments, SunPower is enabling local dealers to capture this strong demand and grow their business," said Peter Faricy, CEO at SunPower.
  • For U.S. dealers interested in joining SunPower's Dealer Accelerator Program, please contact [email protected]
    SunPower is a leading solar and energy services provider in North America.

Color Star Technology Co., Ltd. Announces Entry into Agreement for Registered Direct Placement of Approximately $5.6 Million Ordinary Shares and Warrants

Retrieved on: 
Thursday, September 15, 2022

The gross proceeds from the sale of the securities, before deducting placement agent fees and other estimated offering expenses payable by the Company, will be approximately $5.6 million.

Key Points: 
  • The gross proceeds from the sale of the securities, before deducting placement agent fees and other estimated offering expenses payable by the Company, will be approximately $5.6 million.
  • The Company will issue to the investors an aggregate of 70,000,000 ordinary shares and warrants to purchase an aggregate of 70,000,000 ordinary shares.
  • Such ordinary shares and warrants may be offered only by means of a prospectus, including a prospectus supplement.
  • About Color Star Technology Co., Ltd.
    Color Star Technology Co, Ltd. (Nasdaq: CSCW) is an entertainment and education company that provides online entertainment performances and online music education services.

Larimar Therapeutics Announces $70 Million Underwritten Offering

Retrieved on: 
Wednesday, September 14, 2022

BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar or the Company) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced the pricing of an underwritten offering of 22,225,000 shares of common stock.

Key Points: 
  • BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar or the Company) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced the pricing of an underwritten offering of 22,225,000 shares of common stock.
  • The gross proceeds to Larimar, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $70.0 million.
  • Larimar has granted the underwriters a 30-day overallotment option to purchase up to 3,333,750 additional shares of common stock at the offering price, less underwriting discounts and commissions.
  • Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.